Improving patient outcomes in leukaemia by targeting cancer stem cells

通过靶向癌症干细胞改善白血病患者的预后

• 批准号: nhmrc : 1064569
• 负责人: A/Pr Steven Lane
• 金额: $ 19.65万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Career Development Fellowships
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/improving-patient-outcomes-stem-cells/455126
• 关键词: Improving; patient; outcomes; leukaemia; targeting

Blood cancers such as acute myeloid leukaemia (AML) are among the most deadly types of cancer and new treatments are desperately needed to improve patient’s survival in these diseases. AML cancer-causing stem cells survive by turning on immortalization programs and we hope to specifically kill these AML stem cells by blocking these crucial pathways. This includes things that control the way the cells divide and the way they respond to genetic damage as well as other novel pathways.

血癌如急性髓性白血病（AML）是最致命的癌症类型之一，迫切需要新的治疗方法来提高患者在这些疾病中的生存率。AML致癌干细胞通过启动永生化程序存活，我们希望通过阻断这些关键途径来特异性杀死这些AML干细胞。这包括控制细胞分裂方式和它们对遗传损伤的反应方式以及其他新途径的东西。